Clinical Trials Logo

Renal Transplant Recipient clinical trials

View clinical trials related to Renal Transplant Recipient.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03504241 Active, not recruiting - Clinical trials for Kidney Transplantation

Tolerance by Engaging Antigen During Cellular Homeostasis

TEACH
Start date: July 30, 2018
Phase: Phase 1
Study type: Interventional

Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ. Long-term use of these medicines places transplant recipients at higher risk of serious infections and certain types of cancer. The purpose of this study is to determine if: - it is safe to give mesenchymal stromal cells (MSCs) to kidney transplant recipients, and - the combination of the immunosuppressive (anti-rejection) study drugs plus the MSCs can allow a kidney transplant recipient to slowly reduce and/or then completely stop all anti-rejection drugs, without rejection of their kidney (renal) allograft, a process called "immunosuppression withdrawal".